- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| BIOMED LUBLIN Aktie jetzt für 0€ handeln |
0 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| NOVONESIS | 54,60 | +1,45 % | Novonesis Hosts National Flagship Manufacturing Day Event at North America Headquarters | ||
| GENMAB | 281,90 | +0,25 % | Truist Securities raises Genmab stock price target to $49 on Merus acquisition | ||
| ARBUTUS BIOPHARMA | 3,640 | -1,03 % | Arbutus Biopharma Corp - 8-K, Current Report | ||
| MOLECULIN BIOTECH | 0,510 | -100,00 % | Moleculin Biotech, Inc.: Moleculin Doses First EU Patient in Phase 3 Pivotal MIRACLE Trial for Treatment of Acute Myeloid Leukemia | Spain site opens with two R/R AML subjects enrolled; One treated On track to recruit 45 subjects in 4Q25 for initial data unblinding HOUSTON, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech,... ► Artikel lesen | |
| VERICEL | 29,600 | +3,50 % | Vericel Corporation: Vericel Reports Second Quarter 2025 Financial Results | Total Revenue Growth of 20% to $63.2 Million, with MACI Revenue Growth of 21% to $53.5 Million Gross Margin Increased More than 400 Basis Points to 74% Adjusted EBITDA Growth of 112% to $13.4 Million... ► Artikel lesen | |
| SENSEI BIOTHERAPEUTICS | 11,580 | +5,18 % | Sensei Biotherapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update | - Full data for Phase 1/2 dose expansion cohort expected by year-end 2025 - - Cash runway into the second quarter of 2026 - BOSTON, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics... ► Artikel lesen | |
| BIOXCEL THERAPEUTICS | 2,240 | +4,92 % | BioXcel Therapeutics Regains Compliance with Nasdaq Market Value of Listed Securities Requirements | NEW HAVEN, Conn., Sept. 18, 2025 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in... ► Artikel lesen | |
| MUSTGROW BIOLOGICS | 0,384 | -13,51 % | MustGrow Biologics Corp.: MustGrow Announces Grant of RSUs and DSUs | Saskatoon, Saskatchewan--(Newsfile Corp. - September 26, 2025) - MustGrow Biologics Corp. (TSXV: MGRO) (OTCQB: MGROF) (FSE: 0C0) (the "Company" or "MustGrow") today announced that the board of directors... ► Artikel lesen | |
| REGENXBIO | 10,400 | +14,92 % | The Analyst Verdict: Regenxbio In The Eyes Of 7 Experts | ||
| AKEBIA | 2,500 | -1,11 % | Akebia Therapeutics, Inc.: Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | CAMBRIDGE, Mass., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease... ► Artikel lesen | |
| ZEVRA THERAPEUTICS | 8,850 | +1,14 % | Zevra Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | CELEBRATION, Fla., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living... ► Artikel lesen | |
| FENNEC PHARMACEUTICALS | 8,000 | -1,84 % | Fennec Pharmaceuticals Inc.: Fennec Pharmaceuticals Reports Second Quarter 2025 Financial Results And Provides Business Update | ~ Achieved Second Quarter 2025 Total Net Revenues of $9.7 Million ~ ~ Double Digit New Accounts in the Second Quarter of 2025, Including Notable Quarter-Over-Quarter Growth in Both Large Community... ► Artikel lesen | |
| REVANCE THERAPEUTICS | 3,420 | 0,00 % | AbbVie wins $56M royalty award from Revance in Botox patent infringement case | ||
| CORVUS PHARMACEUTICALS | 6,000 | +1,69 % | Corvus Pharmaceuticals beruft David Moore in den Verwaltungsrat | ||
| CARTESIAN THERAPEUTICS | 8,800 | 0,00 % | Cartesian Therapeutics, Inc.: Cartesian Therapeutics Announces New Employment Inducement Grant | FREDERICK, Md., Oct. 03, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the "Company"), a clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases... ► Artikel lesen |
BIOMED-LUBLIN WYTWORNIA SUROWIC I SZCZEPIONEK SA gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von -0,018 (-1,79 %) liegt der Kurs bei 0,990 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BIOMED-LUBLIN WYTWORNIA SUROWIC I SZCZEPIONEK SA finden Sie auf Wallstreet Online.